Insurance Support Models
Concierge prior authorisation against cash-pay-only.
Released: · Last reviewed:
Concierge prior authorisation against cash-pay-only.
Across the 15 programs we can price at 10 mg, all-in cost runs from $129 to $399 a month, month to month (read October 15, 2026; NexLife as of November 6, 2026). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication plus any mandatory recurring fee, at a named dose, month to month, before tax and before prepaid discounts. Competitor prices read October 15, 2026; NexLife’s as of November 6, 2026. How we verify a price.
What you are actually buying
A telehealth subscription bundles four things that are frequently priced as one: a clinical review, a prescription, fulfilment through a pharmacy, and ongoing access to somebody who will answer a question. Programmes differ enormously in how much of each they provide, and the difference is invisible in a monthly price.
The question that separates care from a vending machine
Can this programme decline to prescribe? A service that guarantees approval before a clinician has seen your history is not running a clinical process, whatever else it discloses. The most reassuring thing a telehealth service can do is turn someone away.
What the care model changes about your bill
Video visits, included laboratory work and real clinician access cost money to provide, and programmes that provide them are rarely the cheapest. That is not a scandal — it is what you are paying for. The failure is paying a premium for an asynchronous questionnaire that a cheaper programme also provides.
What we could not verify
Response times, whether the same clinician sees you twice, and how a programme behaves when something goes wrong. We hold no measurements of those we would defend, so they are absent from every table rather than estimated.
What a subscription actually buys
Four things, usually priced as one: a clinical review, a prescription, fulfilment through a pharmacy, and ongoing access to somebody who will answer a question. Programmes differ enormously in how much of each they provide, and the difference is invisible in a monthly price.
The most expensive programmes are not reliably the ones providing the most. Some are simply carrying more marketing cost, and a cheaper programme that names its pharmacy and answers messages within a day is providing more of what matters.
The test that separates care from a vending machine
Can this programme decline to prescribe? A service that guarantees approval before a clinician has seen your history is not running a clinical process, whatever else it discloses. The most reassuring thing a telehealth service can do is turn somebody away.
Ask what histories would stop a prescription being written. A programme that can answer has clinical governance; one that treats the question as an obstacle does not.
Where asynchronous care is genuinely adequate
For an uncomplicated patient with a clear history, a well-designed questionnaire reviewed by a licensed clinician is a reasonable standard of care and is how a large share of prescriptions in this category are written. It is faster, cheaper and no less careful when the intake is designed to surface contraindications.
It is weaker where the history is complicated, where the answers need follow-up questions, or where somebody is likely to under-report. A video visit is not automatically better care, but it is harder to complete on autopilot.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 15 programs we can price at 10 mg, that runs from $129 to $399 a month all-in, about three times as much at the top as at the bottom, for compounded tirzepatide from the same category of licensed pharmacy.
One of those 15 programs charges a recurring program fee on top of medication, and 10 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
15 of the 32 programs we track have a month-to-month 10 mg price we read on the program’s own site (October 15, 2026; NexLife as of November 6, 2026). The rest print no comparable price, blocked our reader or sell brand Zepbound only, and we show no third-party figure for them. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. Compounded tirzepatide is made with the drug in Zepbound but is not the same product, and FDA does not review it before sale; the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
What you are actually paying a platform for
A telehealth subscription bundles four things frequently priced as one: a clinical review, a prescription, fulfilment through a pharmacy, and ongoing access to someone who will answer a question. Programmes differ enormously in how much of each they provide.
None of that difference is visible in a monthly price, which is why two programmes charging the same figure can be very different purchases.
The test that separates care from a vending machine
Can this programme decline to prescribe? A service guaranteeing approval before a clinician has reviewed a history is not running a clinical process, whatever else it discloses. The most reassuring thing a telehealth service can do is turn someone away.
What we could not measure
Response times, whether the same clinician sees you twice, and how a programme behaves when a shipment fails. Those decide satisfaction more than price does and none is observable from outside, so they are absent from every table here rather than estimated into a score.
The usable proxy is what a programme publishes before it has your money.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.